The prognostic significance of specific HOX gene expression patterns in ovarian cancer by Kelly, Z. et al.
 The University of Bradford Institutional 
Repository 
http://bradscholars.brad.ac.uk 
This work is made available online in accordance with publisher policies. Please refer to the 
repository record for this item and our Policy Document available from the repository home 
page for further information. 
To see the final version of this work please visit the publisher’s website. Access to the 
published online version may require a subscription. 
Link to publisher’s version: http://dx.doi.org/10.1002/ijc.30204 
Citation: Kelly Z, Moller-Levet C, McGrath S et al. (2016) The prognostic significance of specific 
HOX gene expression patterns in ovarian cancer. International Journal of Cancer. 139(7): 1608-
1617.  
Copyright statement: © 2016 The Authors International Journal of Cancer published by John 
Wiley & Sons Ltd on behalf of UICC. This is an open access article under the terms of the Creative 
Commons Attribution License, which permits use, distribution and reproduction in any medium, 
provided the original work is properly cited. 
 
 
 1 
 2 
The prognostic significance of specific HOX gene 3 
expression patterns in ovarian cancer   4 
 5 
Zoe Kelly1 6 
Carla Moller-Levet2 7 
Sophie McGrath1 8 
Simon Butler-Manuel4 9 
Andrzej M. Kierzek2 10 
Hardev Pandha1 11 
Richard Morgan3 12 
Agnieszka Michael1  13 
Thumuluru Kavitha Madhuri4 14 
1 Oncology, School of Biosciences and Medicine, FHMS, Leggett Building, Daphne 15 
Jackson Road, University of Surrey, Guildford GU2 7WG 16 
2 Computational & Systems Biology, School of Biosciences and Medicine, FHMS, 17 
University of Surrey, Guildford, GU2 7TE  18 
1 
 
3 ICT building, Institute of Cancer Therapeutics, University of Bradford, West 19 
Yorkshire, BD7 1DP 20 
4 Royal Surrey County Hospital, Egerton Road, Guildford GU2 7XX 21 
Correspondence: Dr Zoe Kelly 22 
E-mail: z.l.kelly@outlook.com 23 
 24 
Novelty and impact statement 25 
This is the first comprehensive analysis comparing HOX gene expression in ovarian cancer 26 
to normal ovarian and fallopian tube tissue. HOX expression has been analysed along with 27 
the clinico-pathological features of each patient, identifying the significance of specific HOX 28 
genes relating to poor overall survival. This is the first study to analyse changes in HOX 29 
expression with the development of platinum resistance, finding increased expression of 30 
specific genes after resistance occurs, identifying them as potential therapeutic targets.  31 
Abstract 32 
HOX genes are vital for all aspects of mammalian growth and differentiation, and their 33 
dysregulated expression is related to ovarian carcinogenesis. The aim of the current study 34 
was to establish the prognostic value of HOX dysregulation as well as its role in platinum 35 
resistance. The potential to target HOX proteins through the HOX/PBX interaction was also 36 
explored in the context of platinum resistance. HOX gene expression was determined in 37 
ovarian cancer cell lines and primary EOCs by QPCR, and compared to expression in 38 
normal ovarian epithelium and fallopian tube tissue samples. Statistical analysis included 39 
one-way ANOVA and t-tests, using statistical software R and GraphPad. The analysis 40 
identified 36 of the 39 HOX genes as being overexpressed in high grade serous EOC 41 
compared to normal tissue. We detected a molecular HOX gene-signature that predicted 42 
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poor outcome. Overexpression of HOXB4 and HOXB9 was identified in high grade serous 43 
cell lines after platinum resistance developed.  Targeting the HOX/PBX dimer with the HXR9 44 
peptide enhanced the cytotoxicity of cisplatin in platinum-resistant ovarian cancer. In 45 
conclusion, this study has shown the HOX genes are highly dysregulated in ovarian cancer 46 
with high expression of HOXA13, B6, C13, D1 and D13 being predictive of poor clinical 47 
outcome. Targeting the HOX/PBX dimer in platinum–resistant cancer represents a 48 
potentially new therapeutic option that should be further developed and tested in clinical 49 
trials. 50 
Keywords: Ovarian cancer, HOX genes, survival, prognosis, targeted treatment  51 
 52 
Introduction 53 
Ovarian cancer is the 5th leading cause of cancer death in women in the western world and it 54 
is estimated there were 22,280 new cases and 15,500 deaths due to the disease in the US 55 
in 2012 (1). It is the most lethal of the gynaecological malignancies largely due to late 56 
diagnosis. Standard treatment involves debulking surgery followed by a combination of 57 
taxane and platinum-based therapy. Initially most women respond to platinum-based 58 
therapy, but the majority suffer disease recurrence due to drug resistance. It is therefore 59 
essential to introduce new therapeutic approaches to improve treatment at diagnosis and/or 60 
provide an effective second line treatment.  61 
There are different types of ovarian cancer classified by the cell type they originate from. The 62 
most common form, accounting for more than 90% of ovarian cancers, is epithelial ovarian 63 
cancer (EOC), and the high grade serous (HGS) subtype accounts for approximately 80% of 64 
EOC cases.  65 
The epithelial ovarian tumours undergo Müllerian differentiation, which suggests that 66 
differentiation-regulatory factors may contribute to their progression. This mechanism has 67 
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been shown to involve homeobox (HOX) genes (2, 3) which play important roles in tissue 68 
differentiation during embryonic development. The HOX genes constitute a family of 69 
transcription factors, and in mammals 39 HOX genes have been identified. They are 70 
organised into 4 paralogous clusters (A, B, C and D) located on 4 different chromosomes. 71 
During development of the female reproductive system four HOX genes, HOXA9, HOXA10, 72 
HOXA11, and HOXA13 are expressed uniformly along the Müllerian duct axis. HOXA9 73 
becomes expressed in the fallopian tubes, HOXA10 is expressed in the developing uterus, 74 
HOXA11 in the lower uterine segment and cervix and HOXA13 in the upper vagina (4). It is 75 
thought that inappropriate expression of these genes is an early step in epithelial ovarian 76 
neoplasia as they induce aberrant epithelial differentiation. Studies which have analysed 77 
HOX gene expression in ovarian cancer cell lines and a small number of tumours have 78 
found dysregulated expression of certain HOX genes compared to normal tissue (5). 79 
Numerous studies have also demonstrated dysregulated HOX gene expression in other 80 
cancers such as lung, prostate, breast, colon and bladder cancer (6-9). The recent genomic 81 
analysis of HGS ovarian cancer (HGS-OvCa) by the Cancer Genome Atlas (TCGA) 82 
researchers found a number of somatic copy number alterations with three members of the 83 
HOXB family, HOXB2, B5 and B8 among the focally amplified regions. The group divided 84 
HGS ovarian cancer into four expression subtypes ‘immunoreactive’, ‘differentiated’, 85 
‘proliferative’ and ‘mesenchymal’ on the basis of gene expression, and high expression of 86 
HOX genes was a characteristic of the mesenchymal subtype (10). High expression of HOX 87 
genes makes them a potential target for therapeutic intervention. One possible method is the 88 
use of a peptide that disrupts the interaction between HOX proteins and co-factor PBX. 89 
HXR9 is a small peptide designed to mimic the hexapeptide sequence found in HOX 90 
proteins of paralogue groups 1- 9 (11), therefore acting as a specific competitive inhibitor of 91 
the HOX/PBX interaction preventing the subsequent binding of the HOX/PBX dimer to target 92 
DNA sequences. This in effect inhibits the transcription of target genes. Previous studies 93 
have shown that HXR9 is capable of blocking this interaction in vitro and in vivo (11-13) and 94 
antagonising the HOX/PBX interaction induces apoptosis (11-15). 95 
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The role of aberrant HOX dysregulation in EOC is not yet understood. The aim of the current 96 
study was to establish the prognostic value of HOX dysregulation as well as its role in 97 
developing platinum resistance. The potential to target HOX function through the HOX/PBX 98 
interaction was also explored in the context of platinum resistance (13). 99 
 100 
Material and methods 101 
Cell lines and reagents  102 
The human ovarian adenocarcinoma-derived HGS cell line SKOV-3, clear cell carcinoma 103 
derived cell line TOV-21G and the endometrioid carcinoma derived cell line TOV-112D were 104 
obtained from the American Type Culture Collection (LGC Promochem, Teddington, UK). 105 
The SKOV-3 cell line has since been reclassified as an endometrioid subtype due to the lack 106 
of a p-53 mutation and the presence of the endometrioid associated ARID1A mutation (16). 107 
Therefore, the SKOV-3 cell line will be considered as an endometrioid cell line in this paper. 108 
SKOV-3 cells were cultured in McCoys’s 5A modified medium (Sigma, Poole, UK) 109 
supplemented with 10% (v/v) heat-inactivated foetal bovine serum (FBS) (Invitrogen Ltd, 110 
Paisley, UK). TOV-112D and TOV-21G cells were cultured in 1:1 mixture of MCDB 105 111 
medium (Sigma) supplemented with 1.5 g/L sodium bicarbonate and Medium 199 112 
(Invitrogen), with 15% heat-inactivated FBS (Invitrogen). The epithelial HGS carcinoma cell 113 
line derived from peritoneal ascites COV-318 and the paired HGS ovarian carcinoma cell 114 
lines PEO1, PEO4, PEO14 and PEO23 were obtained from the HPA Cell Culture Collection 115 
(HPA, Salisbury, UK) (17). These cell lines were authenticated by either STR profiling (DDC 116 
Medical, OH, USA) or LCG Standards (Middlesex, UK). COV-318 cells were cultured in 117 
DMEM medium (Sigma) with 10% heat-inactivated FBS and 2mM glutamine (Sigma). PEO 118 
cell lines were maintained in RPMI1640 media with 10% heat-inactivated FBS. All media 119 
was supplemented with 1% penicillin (10,000 U/ml) / streptomycin (10 µg/ml) (Sigma). Cell 120 
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cultures were maintained at 37oC in a humidified, 5% CO2 incubator.  Cisplatin sensitivity of 121 
cell lines was verified by MTS assay after 72 hour cisplatin treatment.  122 
RNA isolation, cDNA production and quantitative Real Time PCR (qRT-PCR) 123 
Two total RNA samples from normal human ovarian tissue were purchased from OriGene 124 
(Cambridge, UK). All cell lines were grown in normal growth medium in 6-well plates at a 125 
density range to ensure overnight growth resulted in until 80% confluency before RNA 126 
extraction took place. RNA was isolated from cell lines using the RNeasy® Plus Mini Kit 127 
(Qiagen Ltd, Crawley, UK) following the manufacturer’s instructions. This included the use of 128 
gDNA eliminator columns to remove genomic DNA contamination. Total RNA extracted from 129 
20–30mg ovarian tumour or ovarian normal tissue stored in RNAlater® (Sigma) was isolated 130 
using the gentleMACS dissociator followed by RNA extraction using the RNeasy® Plus Mini 131 
Kit (Qiagen). RNA purity was verified by the 260nm/280nm absorbance ratio, measured 132 
using the Nanodrop (Thermo Fisher, MA). Ratios of 1.9-2.0 were considered ‘pure’ RNA as 133 
described by manufacture. cDNA was synthesised from RNA using the Cloned AMV First 134 
Strand Synthesis Kit (Invitrogen) following the manufacturer’s protocol. qRT-PCR was 135 
performed using the Stratagene MX3005P Real Time PCR machine (Agilent Technologies 136 
UK Ltd, Stockport, UK) and SYBR® Green JumpStart™ Taq ReadyMix™ (Sigma). 137 
Oligonucleotide primers were designed to facilitate the unique amplification of β-actin and 138 
each HOX gene. Melt curves and gels were run originally to validate the primers and check 139 
for single bands of the correct product size. Relative expression was calculated using the 140 
Livak comparative Ct method (18).  141 
Synthesis of HXR9 and CXR9 peptides 142 
HXR9 is an 18 amino acid peptide consisting of the previously identified hexapeptide 143 
sequence that can bind to PBX and nine C-terminal arginine residues (R9) that 144 
facilitate cell entry (11). The N-terminal and C-terminal amino bonds are in the D-145 
isomer conformation, which has previously been shown to extend the half-life of the 146 
peptide to 12 h in human serum (11). CXR9 is a control peptide that lacks a 147 
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functional hexapeptide sequence but still includes the R9 sequence. All peptides 148 
were synthesized using conventional column based chemistry and purified to at least 149 
80 % (Biosynthesis Inc., USA). 150 
 151 
Analysis of cell death and apoptosis 152 
Cells were plated in flat bottomed 96-well plates and incubated for 24 hours until 153 
70% confluent. Cells were treated with HXR9 or CXR9 at a range of dilutions for 2 154 
hours. Cell viability was measured via the MTS assay (Promega, Southampton, UK) 155 
according to the manufacturer’s instructions. To detect morphological changes 156 
consistent with apoptosis, cells were plated in 24-well plates and incubated overnight 157 
to reach 70% confluency. Cells were then treated for 2 hours with 2% FBS media, 158 
the control peptide CXR9 or the active peptide HXR9 at the IC50 (Concentration of 159 
drug needed to induce 50% cell death, as determined by the MTS assay) and double 160 
the IC50. Cells were then harvested by incubating in trypsin-EDTA (Sigma) at 37oC 161 
until detached and dissociated. Apoptotic cells were identified using a Beckman 162 
Coulter Epics XL flow cytometer (argon laser, excitation wavelength 488 nm, FL-2 163 
and FL-4 detectors) and the Annexin V-PE apoptosis detection kit (BD Pharmingen) 164 
as described by the manufacturer’s protocol. Caspase-3 activity was measured using 165 
the EnzCheck Caspase-3 Assay Kit (Molecular Probes), using the protocol defined 166 
by the manufacturer.  167 
 168 
Calculating synergy 169 
To measure synergistic interaction between HXR9 and cisplatin, cells were plated in 170 
a 96-well plate and treated with either HXR9 or cisplatin alone or in combination at 171 
concentrations of the drugs IC50 and ± 2-, 4- and 8- fold this concentration. Cell 172 
viability was then measured by the MTS assay (as described above) and the 173 
presence of synergy was analysed based on the Chou-Talalay method using 174 
CalcuSyn version 2.0 software (Biosoft, Stapleford, UK) (19). The interaction 175 
between HXR9 and cisplatin was quantified by determining the combination index 176 
(CI). Using this method, CI < 1 indicates synergism, CI = 1 indicates an additive 177 
effect antagonism (CI > 1) between drugs.  178 
 179 
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Clinical data 180 
A cohort of 99 patients with corresponding age, stage, time to progression (TTP), overall 181 
survival (OS), histology and chemotherapy information was used in the analysis of primary 182 
ovarian tumours (Supplementary Table 1). Fresh biopsy tissue specimens were obtained 183 
during surgery from human subjects with ovarian cancer or other gynaecological conditions 184 
from the Royal Surrey County Hospital, Guildford following informed consent and ethical 185 
approval. Samples were immediately stored in RNAlater® and stored at -20oC for later use. 186 
Each biopsy was confirmed by a pathologist to be either cancerous of ovarian origin or 187 
normal ovarian tissue. OS and TTP were measured from the date of diagnosis. The duration 188 
of OS was measured up to the date of death or, for patients still alive the 1st October 2012, 189 
when statistical analysis was performed. The duration of TTP was the minimum amount of 190 
time until clinical progression, or death. Only cases where causes of death were due to 191 
disease were used to calculate OS. HOX gene expression was obtained by qRT-PCR and 192 
values were normalised to housekeeping gene β-actin. All sample and data collection 193 
received an ethical approval by the institutional ethics committee (MREC-09/H1103/50). 194 
Mouse in vivo study 195 
All experiments were conducted in accordance with the United Kingdom Co-ordinating 196 
Committee on Cancer Research (UKCCCR) guidelines for the Welfare of Animals in 197 
Experimental Neoplasia (20) and were approved by the University of Surrey Ethics 198 
Committee. The mice were kept in positive pressure isolators in 12 hour light/dark cycles 199 
and food and water were available ad libitum. Six-8 week old female balb/C NUDE mice 200 
(Charles River, Kent, UK) were inoculated subcutaneously with a suspension 100µL Hanks 201 
media (Sigma) containing 106 SKOV-3 cells in 50% matrigel (BD Bioscience).  Once 202 
tumours reached a volume of approximately 100mm3, mice were randomised into 4 203 
treatment groups, each containing 10 mice: PBS alone, Cisplatin alone, HXR9 alone, 204 
Cisplatin and HXR9 in combination. Mice in the HXR9 group received an initial dose of 205 
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100mg/kg HXR9 intratumorally (IT), with subsequent dosing of 10 mg/kg twice weekly. The 206 
cisplatin treatment group received a weekly dose of 3mg/kg via intraperitoneal injection (IP). 207 
PBS was used as a control. Drug concentrations were used based on previous experiments 208 
(13). The mice were monitored carefully for signs of distress, including behavioural changes 209 
and weight loss.  210 
Statistical analysis 211 
All data analysis and manipulation of primary ovarian tumours were performed using R (an 212 
integrated set of software tools for data manipulation, calculation and graphical display).  213 
Four test statistics were used to evaluate the change of gene expression. For variables with 214 
two groups (i.e. Age, OS and chemotherapy) the t-test was used for parametric analysis and 215 
the Mann-Whitney test was used as a non-parametric analysis. For variables with three or 216 
more groups (i.e. TTP and Stage) the one-way ANOVA was used for parametric analysis 217 
and the Kruskal-Wallis was used as a non-parametric analysis. Differential expression and 218 
interactions based on ANOVA. The Benjamini and Hochberg and the Bonferroni correction 219 
was applied to cell line data and ovarian tumour data, respectively, to account for multiple 220 
testing. Principle component analysis (PCA) was performed and the first two principle 221 
components are plotted. The heatmaps include row Z-score transformation (genes), and are 222 
plotted in red–blue colour scale with red indicating high expression and blue indicating low 223 
expression. Analysis of OS was calculated using the Kaplan-Meier method using GraphPad 224 
PRISM Version 5.0 (GraphPad Software). Hazard ratio (HR) and confidence intervals (CI) 225 
were calculated using the Log rank model. 226 
 227 
 228 
 229 
 230 
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Results 231 
HOX gene expression in ovarian cancer cell lines and normal ovarian and fallopian 232 
tube tissue 233 
In order to evaluate the changes in HOX gene expression in EOC we compared the relative 234 
expression of all 39 HOX genes in normal ovarian and fallopian tube tissue to a number of 235 
ovarian cancer cell lines.  236 
The HOX expression profile was analysed in a panel of 5 HGS ovarian cancer cell lines, 2 237 
endometrioid cell lines and 1 clear cell carcinoma cell line and compared with 10 normal 238 
ovarian and 3 fallopian tube tissue samples. A highly dysregulated pattern of HOX gene 239 
expression was found in the EOC cell lines whereas normal tissue showed very little or no 240 
HOX gene expression (Figure 1). 241 
The HGS cell lines showed marked dysregulation but this varied significantly across the 242 
panel. The COV-318 (HGS) cell line showed two HOX genes, with HOXA9, being 243 
significantly upregulated, whilst the PEO14 (HGS) cell line had 23 HOX genes that were 244 
significantly upregulated when compared to normal tissue.  245 
 246 
HOX expression in platinum sensitive and resistant ovarian cancer cell lines 247 
To evaluate differences in HOX expression between platinum sensitive and resistant EOC, 2 248 
paired HGS cancer cell lines derived from patients with platinum sensitive and resistant 249 
disease were analysed. Each pair was acquired from separate patients at the time when the 250 
tumour was deemed clinically sensitive to platinum and at a later time-point after developing 251 
platinum resistance. PEO1 and PEO14 - platinum sensitive cell lines, were compared with 252 
PEO4 and PEO23, platinum resistant cell lines, respectively (21). We found significant 253 
differences in the HOX expression profile in platinum resistant and platinum sensitive cell 254 
lines. The PEO4 (platinum resistant cell line) showed a significant increase of HOXB3 and 255 
HOXB4 gene expression compared to its paired sensitive cell line, PEO1. PEO23 (platinum-256 
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resistant) also has a relatively higher expression of HOXB4 when compared to its platinum-257 
sensitive couterpart-PEO14, and in addition, elevated expression of HOXB9. Cell line gene 258 
expression data was pooled according to platinum sensitivity status and the resistant cell 259 
lines showed an overall higher HOX expression compared to normal and sensitive cell lines 260 
(Figure 2). 261 
HOX expression in primary EOC  262 
To comprehensively evaluate HOX gene expression profiles in clinically relevant HGS EOC 263 
we analysed tumours from a cohort of 73 HGS ovarian cancer patients and compared it to 264 
10 normal ovarian and 3 fallopian tube tissue samples (patients’ characteristics are 265 
summarized in Table 1). HGS ovarian tumours exhibited a significant upregulation in the 266 
expression of 36 of the 39 HOX genes when compared to their expression in normal tissue 267 
samples (Figure 3). The strongly overexpressed genes included HOXA9 (p = 1.86 x 10-8), 268 
previously reported to be related to the HGS histotype (3), however, HOXA3 was expressed 269 
to a far higher level, (p = 9.55 x 10-10).  270 
There were significant differences in HOX expression profiles between the HGS and 271 
endometrioid histological subtypes with up-regulation of HOXA7, A9, A10, A13, B1, B4, B5, 272 
B13, C9, C13, D9 and D10 in the endometrioid samples. HOXB2 was the only gene to show 273 
a significant difference between HGS and clear cell carcinomas, although this might reflect 274 
the small sample size.  275 
A 5-HOX gene signature predicts poor OS 276 
The HOX expression profile in HGS EOC was subsequently correlated with clinical 277 
characteristics such as age, stage, TTP and OS.  278 
The HOX expression profile in EOC also correlated with OS. We found that 5 HOX genes: 279 
HOXA13, B6, C13, D1 and D13 were expressed significantly more strongly in the tumours of 280 
patients with poor survival with higher expression of these genes found in all deceased 281 
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patients. Each of these genes were individually analysed by the Kaplan-Meier method and 282 
the result from the analysis are summarised in Table 1.  283 
Targeting the HOX/PBX dimer in platinum-resistant EOC 284 
The aberrant HOX expression found in EOC makes them a potential therapeutic target. As 285 
the function of HOX genes is partly based on the binding of HOX proteins to the PBX and 286 
MEIS co-factors, targeting these co-factors could impair the oncogenic potential of HOX. 287 
PBX and MEIS proteins are present in both the nucleus and cytoplasm in ovarian 288 
carcinomas, however only MEIS is expressed in normal ovarian epithelia (22). These co-289 
factors are important for ovarian carcinogenesis, most likely through potentiating the function 290 
of HOX proteins. A peptide called HXR9 has been designed to target the interaction between 291 
HOX proteins (members of paralogue groups 1-9) and PBX (11). This drug has been shown 292 
previously to induce apoptosis in cancer cells with highly dysregulated HOX expression 293 
profiles (11, 12, 14, 15), including the ovarian cancer cell line SKOV-3 (13). SKOV-3 is 294 
platinum-resistant, although its origin has recently been questioned (16).   295 
In view of the gross HOX dysregulation pattern seen in platinum-resistant tumours we have 296 
used HXR9 alone and in combination with cisplatin to evaluate its efficacy in this setting. 297 
HXR9 and its control peptide –CXR9 (which has an identical polyarginine cell penetrating 298 
sequence to HXR9 but has a single alanine substitution in its hexapeptide sequence that 299 
renders inactive) have been described previously (11). All cell lines treated with HXR9 300 
demonstrated an increase in cFOS expression, which is thought to be at least partly 301 
responsible for HXR9-induced  cell death (data not shown) (11). When analysed with flow 302 
cytometry for Annexin-V-PE there was a significant increase in the number of cells in late 303 
apoptosis after HXR9 treatment compared to untreated cells (Figure 4a, b). Previous 304 
publications have also demonstrated the apoptosis inducing capacity of HXR9 in ovarian 305 
cancer cell lines showing PARP cleavage and caspase-3 activity in treated cancer cells (11). 306 
The in vitro experiments showed that HGS cell lines were all sensitive to HXR9 treatment but 307 
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not to CXR9 and when combined with cisplatin there was synergy between HXR9 and 308 
cisplatin as shown in Supplementary Table 2. There was also enhanced cell killing in vivo 309 
using a combination of HXR9 and cisplatin over each drug used alone when treating mice 310 
bearing SKOV-3 tumours (Figure 5). Despite a good synergy effect seen in vitro, the effect in 311 
vivo was not as powerful and the combination of HXR9 and cisplatin was only marginally 312 
more active than HXR9 alone. This however may be cell line dependent.  Combined HXR9 313 
and cisplatin provided a survival advantage, with a hazard ratio of 1.98 (95% CI, -0.88–6.58; 314 
p = 0.098) determined by the Log-rank model.  315 
Discussion 316 
This study confirms that HOX genes are highly dysregulated in ovarian cancer and that 317 
targeting the HOX/PBX interaction in platinum resistant tumours is of therapeutic value. Little 318 
to no HOX expression was found in normal ovarian tissue, whereas increased expression of 319 
certain groups of HOX genes was found in the majority of ovarian cancers.  320 
The HGS carcinoma subtype shows the highest degree of heterogeneity in HOX expression 321 
for both cell lines and primary tumours, whereas endometrioid subtypes show a very distinct 322 
HOX expression profile. The HGS histological subtype is known to have a very 323 
heterogeneous nature, exhibiting a wide range of underlying genetic alterations, which may 324 
explain this variation. However, the functional redundancy between HOX genes may mean 325 
the net effect of HOX overexpression is similar even in cells expressing different sets of HOX 326 
genes (23).  327 
Previous studies have shown that the over-expression of specific HOX genes determines the 328 
histological subtype, with HOXA9 being overexpressed in HGS subtypes, HOXA10 in 329 
endometrioid and HOXA11 in mucinous (3). In this study we found that HOXA9 is 330 
overexpressed in only 3 of the 8 HGS cell lines, but is also expressed in the clear cell and 331 
endometrioid cell lines. With regards to the primary tumours, HOXA9 is significantly 332 
overexpressed in the HGS samples; however HOXA10 and HOXA11 are also expressed at 333 
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high levels in HGS tumours, which has not been previously reported. The endometrioid cell 334 
lines show an overall higher level of HOX expression than the HGS cell lines, including 335 
HOXA9 and HOXA10.  336 
HOXA7 has been previously reported to play a role in the differentiation of ovarian surface 337 
epithelia (OSE) into EOC (24). We found that HOXA7 is overexpressed in the HGS cancers 338 
as well as in the endometrioid carcinomas compared to normal ovarian tissue. In addition, 339 
HOXA13 is overexpressed in the endometrioid tumours. This suggests that the HOXA genes 340 
play a role in the determination of histological subtypes, but the differences in expression are 341 
not as clear as previously suggested by Cheng et al. The high expression of HOXA10 in the 342 
endometrioid cell lines and primary tumours does support a role for this gene in the 343 
differentiation of endometrioid tumours; however the high level of heterogeneity in cancer 344 
calls for caution in the interpretation of the results as the level of gene expression may differ 345 
in individual tumour samples. 346 
Although the function of the HOX genes in cancer remains unclear, there have been reports 347 
that they act as tumour suppressor genes or oncogenes. In ovarian cancer both HOXB7 and 348 
B13 expression has been linked to the invasive characteristics of ovarian cancer cells (25), 349 
and HOXB7 has been shown to be a regulator of bFGF- a potent mitogenic and angiogenic 350 
factor (26) and involved in double strand break repair (27), whereas HOXB13 promotes cell 351 
proliferation (28).  352 
We found that 9 out of the 10 HOXB genes were upregulated, the most significant being 353 
HOXB4, B5, B7 and B13. HOXB4 upregulation has been shown to be associated with the 354 
development of platinum resistance in cell lines, and its over-expression in ovarian cancer 355 
has been reported previously in a relatively small study using only 4 cell lines and 7 ovarian 356 
cancer tumour samples (29), but no oncogenic function for this gene has been proven. 357 
HOXB4 has been implicated as a cancer-related gene in other malignancies, including 358 
breast cancer, leukaemia and lung cancer (30-32). The recent genomic analysis of HGS 359 
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ovarian cancer by the Cancer Genome Atlas (TCGA) researchers found a number of 360 
somatic copy number alterations and three members of the HOXB family, HOXB2, B5 and 361 
B8 were among the focally amplified regions (33) further supporting a possible oncogenic 362 
role of HOXB genes in ovarian cancer and emphasising the overlapping functions which 363 
exist between HOX genes (34). 364 
Significant differences in HOX gene expression were found between platinum sensitive and 365 
resistant cell lines. Platinum-resistant cell lines show upregulation of HOX genes from the 366 
HOXB cluster. Although there was a difference between the three paired cell lines tested, 367 
HOXB4 and HOXB9 overexpression was common in two of the three cell lines (when 368 
compared to the platinum-sensitive counterpart). These results therefore demonstrate that 369 
HOXB genes are likely to play a role in developing platinum resistance; although further 370 
work is needed to understand the mechanism of this interaction. 371 
Survival analysis revealed a cluster of 5 HOX genes, HOXA13, B6, C13, D1 and D13, that 372 
was strongly associated with a poor OS in HGS patients. HOXA13 is usually expressed in 373 
the upper vagina (4) playing a role in Müllerian duct differentiation during development, but 374 
has been reported to be overexpressed in ovarian cancer cell lines (25). HOXA13  was 375 
linked to poor OS in oesophageal squamous cell carcinoma patients, and the same study 376 
found its expression in cell lines enhanced tumour growth in vitro and in vivo (35). High-377 
throughput microarray analysis of gastric cancer patients revealed HOXA10 and A13 over-378 
expression with HOXA13 upregulation significantly associated with an aggressive 379 
phenotype, and a prognostic marker for poor OS (36). Highly deregulated expression of the 380 
HOXA cluster has also been found in hepatocellular carcinoma (HCC), in particular HOXA13 381 
(37).  382 
Up-regulation of HOXB6 has also been reported in ovarian cancer before, in addition to 383 
HOXB7 (38). Data from this study and previous reports of high HOXB expression in ovarian 384 
cancer suggests that the HOXB gene products play a role in ovarian tumourgenesis.  385 
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HOXC13 has a role in DNA replication (39), supporting an oncogenic function. A role in 386 
human cancer has also been reported with overexpression found in metastatic melanoma 387 
(40) and fusion with NUP98 has been associated with acute myeloid leukaemia (AML) (41). 388 
The HOXD1 gene appears to be involved in cell differentiation (42), whereas HOXD13 is 389 
deregulated in breast and cervical cancer and melanoma (43-45). A large HOXD13 390 
expression analysis by Cantile and colleagues in 79 different tumour types also supports its 391 
role in neoplastic transformation (46).  392 
Determination of HOX gene dysregulation may be undertaken routinely in the clinical setting 393 
using fresh or archived patient tissue and such information could be used for stratifying 394 
patients in terms of prognosis. Furthermore, we have shown that our novel agent HXR9, a 395 
peptide capable of disrupting HOX gene function by inhibiting HOX binding to its co-factor, 396 
PBX, has significant anti-tumour efficacy (11-15), which is increased when used in 397 
combination with cisplatin. This synergy could be explained due to the role of HOX genes in 398 
DNA repair pathways (27) but further work investigating this is needed. HOX gene 399 
dysregulation therefore represents a potential ovarian cancer target with a low likelihood of 400 
cross resistance to conventional chemotherapeutic agents. Both HXR9 and small molecule 401 
inhibitors of the HOX/PBX dimer are currently being evaluated as novel cancer agents in 402 
preclinical models. 403 
Conclusion 404 
This comprehensive analysis of HOX gene expression in ovarian cancer cell lines and 405 
primary ovarian tumours demonstrates that these genes are profoundly dysregulated 406 
compared to normal ovary. Increased expression of HOXA13, B6, C13, D1 and D13 in EOC 407 
patients is associated with a poor prognosis and a more aggressive malignancy. It is 408 
possible to target HOX function by disrupting its binding to PBX, and further development of 409 
therapeutic compounds to achieve this is warranted.  410 
 411 
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Figure legends 419 
Figure 1 420 
HOX expression in ovarian cancer cell lines of high grade serous (HGS), endometrioid 421 
and clear cell carcinoma subtypes and normal ovarian and fallopian tube tissue. Heat 422 
map showing differential HOX expression between 5 HGS, 2 endometrioid and 1 clear cell 423 
ovarian carcinoma cell lines and 10 normal ovarian and 3 fallopian tube tissue samples. 424 
Expression of each gene was determined by quantitative PCR (qRT-PCR) from at least 425 
three independent experiments and expression is relative to the house keeping gene β-actin. 426 
 427 
 428 
 429 
 430 
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Figure 2 431 
HOX gene expression of paired platinum sensitive and platinum resistant ovarian cancer 432 
cell lines. The comparison of HOX gene expression profiles between patient derived cell 433 
lines before (PEO1 and PEO14) and after (PEO4 and PEO23) developing platinum resistance. 434 
Heat map shows differential HOX expression between platinum sensitivity statuses of cell 435 
lines.  436 
 437 
 438 
 439 
 440 
 441 
 442 
 443 
 444 
 445 
 446 
 447 
 448 
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Figure 3 449 
HOX gene expression in high grade serous ovarian tumours. a) Heat map showing 450 
differentially expressed HOX genes between high grade serous (HGS) ovarian tumours and 451 
normal ovarian and fallopian tube tissue. HOX gene expression data for HGS tumours 452 
(yellow) were compared to 10 normal ovarian tissues (green) and 3 fallopian tube sample 453 
(purple) to find upregulation of 36 genes in the HGS tumours. HOX expression profiles were 454 
determined by quantitative PCR (qRT-PCR) and normalised to housekeeping gene β-actin. 455 
Each column represents a gene and each row represents a sample. Column-wise z-score 456 
transformation (genes) was used. Red colour for a gene indicates expression above the 457 
median and blue indicates expression below the median.  458 
 459 
 460 
 461 
 462 
 463 
 464 
 465 
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Figure 4 466 
HXR9 induces apoptosis in ovarian cancer cell lines. Ovarian cancer cell were assessed 467 
for apoptosis or necrosis through annexin/propidium iodine staining after HXR9 treatment. a) 468 
The bargraphs show the percentage of cells in early apoptosis, late apoptosis, and necrosis, 469 
as well as viable cells, when untreated, treated at the HXR9 IC50 dose or double the IC50 470 
dose for each cell line or equivalent CXR9 dose. Error bars show the SEM. P-values <0.05 471 
are denoted as *, <0.005 ** and < 0.001 as *** with respect to untreated cells. Example flow 472 
cytometry plots for untreated; CXR9 25µM; CXR9 50µM; HXR9 25µM and HXR9 50µM 473 
treated SKOV-3 cells 474 
 475 
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Figure 5 482 
In vivo combination study of HXR9 and cisplatin. Antitumor activity of HXR9 and cisplatin 483 
alone or in combination against ovarian cancer (SKOV-3) xenografts. Nude female mice 484 
were inoculated SC with 1 x 106 SKOV-3 cells (Day 0). Treatment was initiated when 485 
tumours reached an approximate volume of 100m3. An initial dose of HXR9 was given IT at 486 
100 mg/kg, followed by twice weekly doses at 10 mg/kg. Cisplatin was administered IP at 3 487 
mg/kg weekly. Combinational studies consisted of both treatments; PBS was used as a 488 
control. Arrows indicates drug administration. A minimum of 6 mice in each group was set as 489 
the cut-off point for each curve.  490 
 491 
 492 
 493 
 494 
 495 
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Table 1 497 
Kaplan-Meier analysis of the 5-HOX gene prognostic signature showing the median overall 498 
survival for patients who do not express the gene as compared to patients whose tumours 499 
show expression of the genes listed below. Hazard ratios and Confidence intervals were 500 
calculated using the Log rank model 501 
 
Gene 
Median overall 
survival (months) 
 
No. of patients 
 
p values 
 
Hazard ratio 
 
95% Confidence interval 
HOXC13 36 37 0.0128 8.264 1.396–12.75 
HOXB6 36 36 0.0145 8.286 1.365–14.67 
HOXA13 44 39 0.0317 4.508 1.145–12.17 
HOXD13 36 37 0.0308 6.834 1.153–12.79 
HOXD1 36 37 0.025 4.692 1.206–11.61 
 502 
  503 
Supplementary Table 1 504 
Patient characteristics. Tumour samples and patient information was obtained from the 505 
Royal Surrey Hospital, Guildford. 506 
Supplementary Table 2 507 
Synergy between HXR9 and cisplatin in ovarian cancer cell lines. Cells plated in 96-well 508 
plates were exposed to graded concentrations of HXR9 or cisplatin either alone or in 509 
combination. Cells were treated with cisplatin for a total of 72 hours and with HXR9 for 2 510 
hours. Cell viability was then measured by the MTS assay and the presence of synergy was 511 
analysed based on the Chou-Talalay method using CalcuSyn version 2.0 software (Biosoft, 512 
Stapleford, UK) (19). The interaction between HXR9 and cisplatin was quantified by 513 
determining the combination index (CI) at ED50, ED75 and ED90 (doses which produce the 514 
cell kill in 50, 75 and 90 per cent of a population, respectively), where CI < 1 indicates 515 
synergism, CI = 1 indicates an additive effect antagonism (CI > 1) between drugs.  516 
 517 
 518 
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